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Abstract
Introduction: Although sepsis is the leading cause of death in noncoronary critically ill patients, identification of
patients at high risk of death remains a challenge. In this study, we examined the incremental usefulness of adding
multiple biomarkers to clinical scoring systems for predicting intensive care unit (ICU) mortality in patients with
severe sepsis.
Methods: This retrospective observational study used stored plasma samples obtained from 80 severe sepsis patients
recruited at three tertiary hospital ICUs in Hamilton, Ontario, Canada. Clinical data and plasma samples were obtained at
study inclusion for all 80 patients, and then daily for 1 week, and weekly thereafter for a subset of 50 patients. Plasma
levels of cell-free DNA (cfDNA), interleukin 6 (IL-6), thrombin, and protein C were measured and compared with clinical
characteristics, including the primary outcome of ICU mortality and morbidity measured with the Multiple Organ
Dysfunction (MODS) score and Acute Physiology and Chronic Health Evaluation (APACHE) II scores.
Results: The level of cfDNA in plasma at study inclusion had better prognostic utility than did MODS or APACHE II
scores, or the biomarkers measured. The area under the receiver operating characteristic (ROC) curves for cfDNA to
predict ICU mortality is 0.97 (95% CI, 0.93 to 1.00) and to predict hospital mortality is 0.84 (95% CI, 0.75 to 0.94). We
found that a cfDNA cutoff value of 2.35 ng/μl had a sensitivity of 87.9% and specificity of 93.5% for predicting ICU
mortality. Sequential measurements of cfDNA suggested that ICU mortality may be predicted within 24 hours of
study inclusion, and that the predictive power of cfDNA may be enhanced by combining it with protein C levels
or MODS scores. DNA-sequence analyses and studies with Toll-like receptor 9 (TLR9) reporter cells suggests that
the cfDNA from sepsis patients is host derived.
Conclusions: These studies suggest that cfDNA provides high prognostic accuracy in patients with severe sepsis.
The serial data suggest that the combination of cfDNA with protein C and MODS scores may yield even stronger
predictive power. Incorporation of cfDNA in sepsis risk-stratification systems may be valuable for clinical decision
making or for inclusion into sepsis trials.
Introduction
Sepsis is a devastating condition characterized by sys-
temic activation of inflammatory and coagulation path-
ways in response to microbial infection of normally
sterile parts of the body [1,2]. Microbial invasion origi-
nates from a breach of integrity of the host barrier, either
physical or immunologic. Sepsis is the leading cause of
death in critically ill patients and is a leading cause of
morbidity and mortality in the Western world [3]. Severe
sepsis, defined as sepsis associated with at least one dys-
functional organ, afflicts approximately 750,000 people in
the United States annually, with an estimated mortality
rate of 30% to 50% [3].
The identification of highly reliable outcome predictors
in severe sepsis is important to describe disease severity
for bedside prognosis, to assist deciding on location of
care, to monitor response to treatment, and to stratify or
enroll patients in clinical trials. However, the heterogeneity
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of patients with severe sepsis makes the identification of
those at high risk of death a challenge, both for clinical
and research purposes.
Various clinical scoring systems have been developed
to facilitate evaluation of disease severity, each with its
own limitations [4]. These scoring systems can be divided
into two main classes. The first class of scoring system
assesses disease severity primarily through evaluation of
physiological parameters (for example, Acute Physiology
and Chronic Health Evaluation [APACHE] II score [5]).
These scores are somewhat laborious to use and are
primarily considered at the time of admission to the
intensive care unit (ICU). In contrast, organ-dysfunction
scores can more readily be measured over time and thus
capture the dynamics of organ dysfunction, including the
patients’ response to therapeutic interventions. Examples
are the Multiple Organ Dysfunction Scores [MODS] [6]
and Sequential Organ Failure Assessment [SOFA] [7]
scores. However, both of these classes of scoring systems
focus only on physiological abnormalities, and they are
not exclusive to patients with sepsis syndrome. Further-
more, these scores have only a moderate discriminative
power with respect to ICU mortality. With receiver oper-
ating characteristic (ROC) curves [8], which measure the
diagnostic accuracy of a given test, the area under the
curve (AUC) for these scores ranges from 0.6 to 0.7 [9].
Several biomarkers have been proposed to be of poten-
tial use for sepsis prognostication, including inflammatory
cytokines, cell-surface markers, acute-phase proteins, coa-
gulation factors, and apoptosis mediators [10,11]. Recent
research suggested that cell-free DNA (cfDNA), released
as a result of cell necrosis or of apoptosis, may have prog-
nostic utility in a range of conditions, including cancer
[12], trauma [13], stroke [14], myocardial infarction [15],
and sepsis [16,17]. However, sample sizes in these biomar-
ker studies remain small, and it is unclear whether any
one marker could predict outcome in a complicated con-
dition such as sepsis.
The objective of this study was to examine the incre-
mental usefulness of adding multiple biomarkers to clini-
cal scoring systems for predicting ICU mortality in
patients with severe sepsis. We examined the following
variables in 80 patients with severe sepsis: age, acute phy-
siology and chronic health evaluation (APACHE II)
scores, multiple organ-dysfunction scores (MODS), IL-6
(a proinflammatory cytokine), thrombin (a procoagulant
factor), protein C (an anticoagulant factor), and cfDNA.
We chose these biomarkers to capture a broad spectrum
of physiologic derangements that may be important in
sepsis pathophysiology [18-20]. Herein, we report the
prognostic value of cfDNA in a cohort of patients with
severe sepsis. We also characterized the biochemical
properties of cfDNA in sepsis patients.
Materials and methods
Patients and plasma samples
Frozen plasma samples were obtained from an available
biobank of 80 severe sepsis patients. The patients were
recruited between March 2001 and September 2007
from three academic, tertiary care ICUs in Hamilton,
Ontario. Patients with severe sepsis were identified by
using the inclusion and exclusion criteria as described
by Bernard et al. [21]. The management of the patients
was left to the attending ICU team, following published
practice during that time period. Patients who received
recombinant Activated Protein C (rAPC) therapy were
excluded from the study. This study was approved by
the Research Ethics Board of McMaster University and
the Hamilton Health Sciences, Hamilton, Ontario,
Canada (REB approval 01-195). Written informed con-
sent was obtained from the patient (or substitute deci-
sion-maker) or from the healthy controls before blood
collection.
The patient blood samples were collected within
24 hours of meeting the inclusion criteria for severe sepsis
in the ICU. The blood was processed within 2 hours of
blood collection. In brief, venous blood (9 ml total) was
collected from indwelling catheters and transferred into
15-ml polypropylene tubes containing 0.5 ml of 0.105 M
buffered trisodium citrate (pH 5.4). The blood was centri-
fuged at 1,500 g for 10 minutes at 20°C, and the plasma
was stored as 200-μl aliquots at -80°C and thawed at the
time of assays.
Plasma samples from healthy controls
Plasma samples were obtained from 14 healthy adult
volunteers who were not receiving any medication at
the time of blood sampling. No attempt to match cases
and controls was made.
Quantification of cfDNA levels in plasma
cfDNA was isolated from 250 μl of plasma by using the
QIAamp DNA Blood Mini Kit (Qiagen, Valencia, CA,
USA). The concentration of the DNA was measured with
UV absorbance at 260 nm by using a spectrophotometer
(Beckman DU 7400; Beckman Coulter Inc., Brea, CA,
USA). The purity of the DNA was confirmed by deter-
mining the OD260/OD280 ratio and by the BCA Protein
Assay (Pierce, Rockford, IL, USA).
Measurement of IL-6, thrombin-antithrombin (TAT)
complexes, and protein C in sepsis plasma
IL-6 levels in plasma samples were determined by using
the Human IL-6 ELISA Development kit (Biovision,
Mountain View, CA, USA). Levels of TAT complexes
were quantified by the Enzygnost TAT micro kit (Dade
Behring Inc., Marburg, Germany). Total protein C antigen
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in citrated plasma samples was quantified with an enzyme
immunoassay (Affinity Biologicals Inc., Ancaster, ON,
Canada).
Stimulation of Toll-like receptor 9 (TLR-9) reporter cells
with cfDNA
To distinguish bacterial DNA from mammalian DNA, we
used 293XL-hTLR9 cells, a human TLR9 reporter cell line
(InvivoGen, San Diego, CA, USA). To monitor the translo-
cation of nuclear factor B (NF-B; which is induced by
TLR-9 signaling), we used the pNiFty2 plasmid, which
encodes a reporter gene encoding secreted alkaline phos-
phatase (SEAP). Expression of SEAP is controlled by an
NF-B-inducible promoter. The positive control was
ODN 2006, a synthetic oligonucleotide that contains
unmethylated CpG dinucleotides in particular sequence
contexts (InvivoGen).
DNA sequence analyses of cfDNA from severe sepsis
patients
The prominent DNA bands from the severe sepsis patients
(that is, the ~150-bp and ~300-bp DNA bands) were
excised from 1.5% agarose gels, blunt ended, inserted into
the cloning vector (Litmus 28i), and sequenced.
Statistical analyses
The LOGISTIC procedure of SAS (version 9.2) was used
to assess the dependency of the probability of dying on
each predictive variable (either clinical score or biomarker)
or on a combination of several variables. By using the vari-
ables created by the OUTROC option of the MODEL
statement in the LOGISTIC procedure [22], the ROC
curves were drawn by using Excel, and the AUCs and
their standard errors were computed by using SAS codes,
based on the distribution-free formulas provided by
Hanley and McNeil [8]. In constructing the 95% confi-
dence intervals for AUC, the critical value (1.96), based on
the assumption of the standard normal distribution, is
replaced by the critical value based on a t-distribution
with (n-p-1) degrees of freedom, where n is the sample
size, and p is number of explanatory variable(s) used in
the logistic model. This replacement has the advantage of
allowing the confidence interval to be somewhat wider for
the AUC that is generated by more than one explanatory
variable. The reason for this replacement is that the use of
more explanatory variables results in a reduction in
degrees of freedom, which in turn leads to a reduction in
confidence.
For temporal changes in biomarkers, analysis of variance
(ANOVA) was used to compare the results between survi-
vors and nonsurvivors. For temporal changes in biomar-
kers, SigmaPlot graphs were used to distinguish the
patterns between survivors and nonsurvivors. For each
biomarker, the statistical significance of the gap between
these two groups of patients was assessed by analysis of
variance (ANOVA).
Results
Prognostic utility of cfDNA in severe sepsis patients
The baseline (day 1) characteristics of the 80 severe sepsis
patients are shown in Table 1 (“baseline” is defined as
within 24 hours of meeting the inclusion criteria for severe
sepsis in the ICU). We found that the mean baseline level
of cfDNA in survivors (1.16 ± 0.13 ng/μl; n = 46) was simi-
lar to that in healthy volunteers (0.93 ± 0.76 ng/μl; n = 14)
(P = 0.426), whereas the mean cfDNA levels in nonsurvi-
vors are markedly higher (4.65 ± 0.48 ng/μl; n = 34) com-
pared with survivors (P < 0.001) and with healthy
volunteers (P < 0.001). The mortality rates increased
across increasing quartiles of baseline plasma cfDNA levels
(5% in the first quartile, 60% in the second quartile, 83% in
the third quartile, and 100% in the fourth quartile). In con-
trast, the mortality rates in the highest quartiles of baseline
APACHE II score, MODS score, and age were 36%, 64%,
and 50%, respectively.
Applying a binomial logistic model to the baseline
data, we generated receiver operating characteristic
(ROC) curves to determine the predictive power of each







Mean ± SEM (min, max) 60 ± 2.2 (20,
84)
68 ± 2.3 (37, 87)
Gender, % female (no./total) 30.4 (14 of 46) 32.3 (11 of 34)
APACHE II score
Mean ± SEM (min, max) 21.6 ± 1.2 (7,
40)
24.5 ± 1.1 (10,
34)
MODS score
Mean ± SEM (min, max) 8.3 ± 0.56 (2,
17)
10.4 ± 0.62 (3,
17)
Primary site of infection, no. (% of
total)
Lung 24 (52.1%) 18 (52.9%)
Blood 11 (23.9%) 4 (11.8%)
Urinary tract 1 (2.2%) 3 (8.8%)
Abdomen 5 (10.9%) 1 (2.9%)
Skin 2 (4.3%) 0 (0%)
Other 1 (2.2%) 5 (14.7%)
Unknown 2 (4.3%) 3 (8.8%)
Positive cultures, no. (% of total)
Gram-negative bacteria 8 (17.4%) 3 (8.8%)
Gram-positive bacteria 16 (34.8%) 9 (26.5%)
Fungus 2 (4.3%) 4 (11.8%)
Mixed 11 (23.9%) 14 (41.2%)
Unknown 9 (19.6%) 4 (11.8%)
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clinical score and biomarker for ICU mortality. The area
under the curve (AUC) for each ROC curve is summar-
ized in Table 2. With an AUC value of 0.97 (95% CI,
0.93 to 1.00), cfDNA has the strongest predictive power
among the eight predictors listed in Table 2. In this
cohort of patients, MODS score, APACHE II score, and
age have modest predictive powers, with AUC values of
0.63 (95% CI, 0.50 to 0.75), 0.64 (95% CI, 0.52 to 0.77),
and 0.66 (95% CI, 0.54 to 0.78), respectively. Thrombin-
antithrombin complexes (TAT), protein C, IL-6, and
gender have no statistically significant predictive power
because the AUC of each of them has a 95% confidence
interval that spans the AUC for a completely random
process: 0.5.
The ROC curves for cfDNA, MODS, and APACHE II
are displayed in Figure 1. For cfDNA, the best cutoff
value that maximizes the sum of sensitivity and specifi-
city is 2.35 ng/μl, a value that yields a sensitivity of
87.9% (95% CI, 77.2 to 99.2) and specificity of 93.5%
(95% CI, 86.2 to 100) for predicting ICU mortality. By
using the baseline data, we also found that combining
cfDNA with any of the other seven predictors does not
contribute to any statistically significant improvement in
the model’s predictive power beyond that achieved by
cfDNA alone (data not shown). With respect to hospital
mortality, the AUC of cfDNA is 0.84 (95% CI, 0.75 to
0.94), which is higher than the corresponding AUCs of
all other predictors.
We also calculated the positive predictive values (PPVs)
and negative predictive values (NPVs) for cfDNA and
other variables (APACHE II, MODS, age, TAT complexes,
protein C, IL-6, gender). As shown in Table 3, the prog-
nostic utility of baseline levels of cfDNA is indicated by a
PPV = 0.91 (95% CI, 0.81 to 1.00) and NPV = 0.91 (95%
CI, 0.83 to 1.00), which are greater than the corresponding
PPVs and NPVs of the other variables.
Temporal changes in cfDNA, protein C, and MODS in
severe sepsis patients
In the 80 severe sepsis patients, serial plasma samples
and MOD scores were available in 50 of the patients (16
survivors, 34 non-survivors). These serial samples and
MODS scores were collected in the ICU on days 1
through 7, and then on days 14, 21, and 28. Figure 2A
summarizes the temporal changes in cfDNA in these
patients. With ANOVA, we found a highly significant dif-
ference between cfDNA levels in survivors and nonsurvi-
vors over the course of 28 days (t = 19.61). Furthermore,
levels of cfDNA at day 1 did not differ significantly from
the levels measured in subsequent days. In other words,
cfDNA levels in nonsurvivors were high at baseline and
remained high; cfDNA levels in survivors were low and
remained low.
Abnormalities in coagulation parameters are routinely
observed in patients with severe sepsis [23-25]. In this
study, we also examined temporal changes in the anticoa-
gulant factor protein C in plasma from severe sepsis
patients (Figure 2B). Relative to healthy volunteers, all sep-
sis patients had reduced levels of protein C at day 1,
although no statistically significant difference in protein C
levels was found between survivors and nonsurvivors.
However, patients who survived exhibited an early return
of protein C levels to near-normal levels (P < 0.01 when
comparing day-1 with day-6 levels of protein C in survi-
vors). In contrast, patients who died exhibited no increase
in protein C levels during the course of their ICU stay.
The overall difference in protein C level between the
Table 2 ROC analysis to predict ICU mortality in a cohort
of 80 severe sepsis patients




cfDNA 0.97 0.93 to 1.00
APACHE II 0.64 0.52 to 0.77
MODS 0.63 0.50 to 0.75
Age 0.66 0.54 to 0.78
TAT
complexes
0.57 0.44 to 0.70
Protein C 0.57 0.43 to 0.70
IL-6 0.56 0.43 to 0.69
Female gender 0.51 0.39 to 0.65
ROC curves were generated to determine the predictive power of each
variable (baseline values) for ICU mortality. The AUCs for each ROC curve are
summarized here.
1-Specificity












Figure 1 Receiver operating characteristic (ROC) curves for cfDNA
(∙), MOD score (□), and APACHE II score (Δ) to predict ICU
mortality in 80 patients with severe sepsis. By using a binomial
logistic model, we generated ROC curves to determine the predictive
power of baseline values of cfDNA, MODS score, and APACHEII score
for ICU mortality. The area under the curve (AUC) for cfDNA is 0.97
(95% CI, 0.93 to 1.00), for APACHE II score, is 0.64 (95% CI, 0.52 to 0.77),
and for MODS score, is 0.63 (95% CI, 0.50 to 0.75).
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survivors and nonsurvivors is significantly different from
zero (t = -3.34).
Time-dependent changes in the MODS scores are
shown in Figure 2C. No statistically significant differ-
ence in MODS scores appeared between survivors and
nonsurvivors at day 1. However, serial measurements
reveal that although the MODS scores of the nonsurvi-
vors tended to remain at a high level, the MODS scores
of the survivors decreased with elapsed time, resulting
in a significant overall difference between the two
groups of patients (t = 8.85).
As reflected by the magnitude of the t statistic, the
overall difference between the survivors and nonsurvi-
vors over time was the greatest for cfDNA and the
smallest for protein C. Thus, if we use the average value
(across all available plasma samples for each patient) for
cfDNA, MODS, or protein C in the ROC analysis to
determine the predictive power of each variable for ICU
mortality, we would expect the AUC to be the greatest
for cfDNA and the smallest for protein C. As expected,
we find that the resulting AUC is 0.96 (95% CI, 0.92 to
1.00) for cfDNA, 0.77 (95% CI, 0.66 to 0.88) for MODS,
and 0.64 (95% CI, 0.51 to 0.77) for protein C.
Because serial measurements of cfDNA, MODS, and
protein C, averaged across blood samples, tend to be at a
lower risk for random and nonrandom errors than the
baseline data, we explored the possibility that combining
either MODS, or protein C, or both with cfDNA may
enhance the predictive power of cfDNA. We found that
combining average MODS with average cfDNA increases
the AUC from 0.965 to 0.969, whereas combining aver-
age protein C with average cfDNA increases the AUC to
0.977. Both of these increases are statistically significant
(the P values are 0.027 and 0.008 for the coefficient of
average MODS and average protein C, respectively).
Combining both average MODS and average protein C
with average cfDNA increases the AUC further to 0.981.
However, the coefficient of MODS is not significantly dif-
ferent from zero. It is useful to note that, even though
average protein C is weaker than average MODS in
predictive power when used alone, the former enhances
the predictive power of average cfDNA to a greater
extent than does the latter, because a greater overlap in
predictive power exists between average MODS and aver-
age cfDNA.
An important finding is that the simultaneous use of
average cfDNA and average protein C to make predic-
tions of ICU deaths increases sensitivity without sacrifi-
cing specificity. The best cut-off point is 2.47 ng/μl for
average cfDNA and 0.66 U/ml for average protein C. At
this value, sensitivity is increased from 87.9% (95% CI,
77.2 to 99.2) to 97.1% (95% CI, 91.3 to 100), whereas spe-
cificity remains at 93.5% (95% CI, 86.2 to 100). The
assessment of the average variables in terms of PPV and
NPV yields similar inferences (Table 4). With PPV = 0.84
(95% CI, 0.72 to 0.96) and NPV = 0.93 (95% CI, 0.85 to
1.00), the prognostic utility of average cfDNA is greater
than those of average MODS and average protein C. The
prognostic utility of average cfDNA is enhanced by com-
bining with either average MODS or average protein C.
With PPV = 0.92 (95% CI, 0.82 to 1.00) and NPV = 0.98
(95% CI, 0.93 to 1.00), the combination of average
cfDNA and average protein C is of the greatest prognos-
tic utility.
Taken together, these studies suggest that cfDNA may
predict ICU death better than other predictors examined
in this study, and that using the information obtained
from repeated measurements, the predictive power of
cfDNA can be enhanced by combing it with protein C
or MODS in a multivariate statistical model.
Relation of cfDNA to type of sepsis
To study the relation between cfDNA and causative
microorganisms, each case of sepsis was classified in one
of five class groupings: Gram-positive bacteria, Gram-
negative bacteria, fungal, mixed microbial infections, and
unknown or none. The number of patients in each
grouping is summarized in Table 1. We observed no sta-
tistically significant difference in cfDNA levels among
these groupings.
Table 3 Positive predictive value (PPV) and negative predictive value (NPV) for assessing the prognostic utility of the
baseline values of cfDNA and other variables
Variable Positive predictive value 95% CI Likelihood ratio
c2
Negative predictive value 95% CI Likelihood ratio
c2
cfDNA 0.91 0.81-1.00 25.64 0.91 0.83-1.00 37.80
APACHE II 0.55 0.42-0.69 0.64 0.88 0.74-1.00 15.19
MODS 0.65 0.45-0.85 2.16 0.67 0.54-0.79 6.46
Age 0.53 0.39-0.68 0.19 0.73 0.57-0.88 7.07
TAT complexes 0.59 0.40-0.77 0.87 0.65 0.52-0.79 4.67
Protein C 0.64 0.43-0.84 1.66 0.66 0.53-0.78 5.68
IL-6 0.86 0.59-1.00 3.96 0.61 0.50-0.73 3.59
Female gender 0.44 0.30-0.57 0.89 0.60 0.40-0.80 1.01
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Source of cfDNA: host versus microbe?
TLR9 is expressed by many cell types in the intestinal
tract, including epithelial cells, dendritic cells, and
macrophages [26]. The stimulatory ligand for TLR9 is
unmethylated cytosine-guanine (CpG) DNA, a microbial
product that is recognized by the vertebrate innate
immune system. Engagement of TLR9 can elicit an
inflammatory response through activation of the Rel/
NF-B transcription factor family and secretion of
proinflammatory cytokines [27]. By using 293XL-hTLR9
reporter cells, we determined the levels of NF-B activa-
tion by these cells in response to cfDNA from healthy
volunteers (n = 5) and from severe sepsis patients (n =
18). None of these samples stimulated the production of
SEAP from the 293XL-hTLR9 cells, suggesting that the
cfDNA from severe sepsis patients is host derived (data
not shown).
To visualize the cfDNA from severe sepsis patients, we
subjected the DNA to agarose gel electrophoresis. We
observed that nine of 80 patients had two prominent
DNA bands of ~150 bp and ~300 bp (Figure 3). For the
remaining 71 patients, no prominent bands or distinct
fragmentation patterns were observed, even after con-
centrating the DNA 10-fold (data not shown). cfDNA
isolated from five healthy volunteers also did not show
prominent bands (data now shown). To determine the
DNA sequence composition of the two prominent
bands, the bands were excised from the gels, inserted
into a cloning Vector (Litmus 28i), and sequenced.
Table 3 shows sample DNA sequences obtained from
these prominent bands. These sequences were identified
with nucleotide BLAST (blastn) against human and
microbial reference genomic sequences. BLAST results
indicated overall closer identity to human genomic
sequences (97% to 100% identity) than to microbial
sources (Table 5). No human mitochondrial sequences
were identified from these two prominent bands,
although we acknowledge that the total number of
sequences that we obtained from our cloning strategy
was small. Taken together, these two sets of experiments
indicate that the cfDNA is host derived.
Potential confounding by renal failure
Because renal impairment is common in severe sepsis,
we demonstrated that cfDNA values are not influenced
by impaired renal function (that is, no correlation was
found between the cfDNA and the glomerular filtration
rate (r = -0.17)).
Discussion
DNA can be released from various host cells including
neutrophils [28-30], macrophages [31], eosinophils [32],
Days in ICU































































































Figure 2 Temporal changes in levels of cfDNA (A), PC (B), and
MOD score (C) in 50 patients with severe sepsis. Survivors are
shown by white circles (o), and nonsurvivors are shown by black
circles (●). The number of patients at each time point (for which
cfDNA, PC, or MODS values are available) is indicated in each graph.
Data are shown as the mean ± SEM. The mean levels of cfDNA and
PC in healthy volunteers (n = 14) is shown by the arrows.
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and tumor cells [33]. Neutrophil extracellular traps
(NETs), composed of chromatin and granular proteins,
not only ensnare bacteria, but also possess neutrophil
enzymes that can kill microbes [28]. It has been pro-
posed that NETS and platelet-neutrophil aggregates may
hinder the flow of blood in the microcirculation, thereby
leading to tissue hypoxia and endothelial damage
[29,34]. DNA can also be released by certain strains of
bacteria [35,36]. Release of bacterial DNA facilitates the
adherence and colonization of bacteria to an inert or liv-
ing surface [37] and occurs through the release of small
membrane vesicles [38].
We demonstrated that the AUC for cfDNA to predict
ICU mortality was 0.97 (95% CI, 0.93 to 1.00), suggesting
that cfDNA isolated from plasma is a superior discrimina-
tor compared with other scoring systems and/or biomar-
kers [11,25,39,40]. We also studied the time-dependent
changes in cfDNA in our sepsis patients. Sequential mea-
surement of cfDNA levels revealed that no overlap occurs
in cfDNA levels between survivors and nonsurvivors dur-
ing the course of the patients’ stay in the ICU. This raises
the possibility that at a very early stage in severe sepsis,
the nonsurviving patients had already reached “a point of
no return” given standard clinical management. Thus, in
addition to prognostication, levels of cfDNA may be useful
in stratifying for inclusion in clinical trials (for example,
selecting the most severe cases) or for monitoring
response to newer antisepsis therapies or procedures. For
example, it is unknown if the current sepsis guidelines for
early fluid resuscitation and treatment can modify the pro-
duction of cfDNA [41].
We also measured temporal changes in protein C and
in MODS scores in our cohort of severe sepsis patients.
The levels of protein C in our patients are consistent
with those published by other studies. For example, we
observed that patients who survived exhibited an early
directional change in protein C levels to near-normal
levels. This finding is consistent with retrospective eva-
luation of protein C levels in the placebo patients of the
PROWESS (Recombinant human activated protein C
worldwide evaluation in severe sepsis) trial [42,43].
Indeed, sequential measurements of protein C levels
were used to guide administration of rAPC, as reported
in the phase II RESPOND trial (Research Evaluating
Serial Protein C levels in severe sepsis patients on Dro-
trecogin alfa [activated]) [44,45]. With respect to serial
MODS scores, our data reveal that although the MODS
scores of the nonsurvivor patients tended to remain at a
high level, the MODS scores of the survivors improved
(that is, decreased) over time. This finding is consistent
with previous reports that daily MODS scores provide
additional prognostic value over baseline MODS [46].
Importantly, our data also suggest that the predictive
power of cfDNA can be enhanced by combing it with
protein C or MODS in a multivariate statistical model.
To date, only one large study (n = 225 patients) exam-
ined the prognostic utility of cfDNA in severe sepsis
[16]. This study by Saukkonen et al. [16] reported that
cfDNA concentrations had only moderate discriminative
power for ICU mortality (AUC = 0.71 in an ROC curve,
95% CI 0.62 to 0.80), no better than that of clinical
scores. In another study of 52 general ICU patients (19
of whom were septic), Rhodes et al. reported that the
AUC in ROC analysis for baseline cfDNA to predict
ICU mortality is 0.84 (95% CI, 0.71 to 0.97) [17].
Table 4 Positive predictive value (PPV) and negative predictive value (NPV) for assessing the prognostic utility of the
average cfDNA, average MODS, and average protein C
Variable Positive predictive value 95% CI Likelihood ratio
c2
Negative predictive value 95% CI Likelihood ratio
c2
cfDNA 0.84 0.72-0.96 18.49 0.93 0.85-1.00 37.85
MODS 0.70 0.54-0.86 5.26 0.77 0.64-0.89 14.01
Protein C 0.74 0.54-0.94 4.44 0.67 0.55-0.79 7.38
cfDNA and MODS 0.91 0.81-1.00 26.84 0.93 0.86-1.00 41.59




Figure 3 Agarose gel electrophoresis of cfDNA from severe
sepsis patients. cfDNA was purified from 250 μl of plasma, as
described in Materials and methods, and 16 μl was loaded per lane.
Lanes 1 to 5, cfDNA from severe sepsis patients (survivors); lanes 6
and 7, cfDNA from severe sepsis patients (nonsurvivors); lane 8, 100-
bp DNA ladder.
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Table 5 Sample sequences of cfDNA from severe sepsis patients






































































































The major difference between our study and previous
reports is the method by which cfDNA levels were
quantified. Previous reports quantified cfDNA by using
real-time quantitative PCR for the b-globin housekeep-
ing gene, thus detecting a subset of cfDNA; specifically,
it would detect nuclear DNA which contains copies of
the b-globin gene, but not mitochondrial DNA or DNA
from microbial origins. Mitochondrial DNA has been
shown to contribute to the inflammatory response in
trauma and hemorrhagic shock [47-49]. Furthermore,
the PCR-based method for quantifying DNA can be
influenced by the fragmentation grade of the DNA in
that some degraded b-globin gene copies may not be
amplified, resulting in an underestimation of DNA
levels. In contrast, because our method of DNA quanti-
fication is based on the absorbance at 260 nm, we are
able to measure the levels of cfDNA, irrespective of the
source or the fragmentation grade of the DNA. By using
RT-PCR probing for the b-globin gene, we found that
the PCR-based method detected approximately 10-fold
less DNA compared with the UV-absorbance method at
280 nm (data not shown).
We observed no difference in cfDNA levels among
patients with Gram-positive, Gram-negative, fungal,
mixed, or unknown infections. Thus, the release of
cfDNA from host cells occurred independent of the
infecting organism and hence is likely mediated by the
inflammatory mediators generated during the exacer-
bated host response to infection. We also did not find a
relation between cfDNA levels and renal function. These
findings are consistent with previous reports that exam-
ined the association between nucleosome levels, microor-
ganisms, and renal function in patients with systemic
inflammation, sepsis, and septic shock [50]. Nucleosomes
are the basic units of DNA packaging in cells, consisting
of DNA fragments of approximately 147 bp wound
around histone core proteins [51]. Although the sample
size was small, the study reported a relation between
nucleosome levels and disease severity but not with
microorganisms or renal function [50].
Apoptotic cells typically release DNA “ladders” consist-
ing of multiples of 180-bp fragments [52], whereas necrotic
cells contain DNA fragments larger than ~10,000 bp [53].
Agarose gel electrophoresis revealed that cfDNA from
nine of 80 patients had two prominent DNA bands of
~150 bp and ~300 bp (Figure 3). DNA sequence analyses
indicated that the DNA within these bands is of host ori-
gin, representative of both noncoding and coding portions
of the human genome. We hypothesize that the two pro-
minent DNA bands represent nucleosome units that are
resistant to degradation by circulating DNase enzymes.
Recent studies showed that extracellular histones are
major mediators of death in animal models of sepsis [54]
and that histones activate TLR-2 and TLR-4 [55]. In
addition, histones promote thrombin generation via plate-
let-dependent mechanisms and by impairing thrombomo-
dulin-dependent protein C activation [56,57].
Furthermore, we and others have shown that extracellular
DNA activates the blood-coagulation cascade [58,59].
Thus, elevations of cfDNA likely reflect a severe pathologic
condition whereby DNA and/or histones exert proinflam-
matory and procoagulant effects.
Limitations to our studies include the following. The
sample size is small (n = 80), and the stored plasma sam-
ples were obtained from severe sepsis patients recruited
between 2001 and 2006. The patients were recruited on
the basis of convenience because of limitations in funding
and research personnel. Thus, bias may have been gener-
ated by nonconsecutive patient enrollment. We are cur-
rently validating our findings prospectively with
consecutive enrollment in a large, multicenter, observa-
tional study (ClinicalTrials.gov Identifier: NCT01355042).
Conclusions
In summary, we identified a biomarker that appears to
have high discriminative power to predict ICU mortality in
a cohort of patients admitted to the ICU with severe sepsis.
These data are also the first to reveal the time-dependent
changes in cfDNA levels in patients with severe sepsis. The
serial data suggest that the combination of cfDNA with
protein C and MODS scores may yield even stronger pre-
dictive power. Incorporation of cfDNA in sepsis risk-strati-
fication systems (for example, the PIRO model for staging
severe sepsis [60,61]) may be valuable for clinical decision
making or for inclusion into sepsis trials.
Key messages
• cfDNA appears to have high discriminative power to
predict ICU mortality in patients with severe sepsis.
• Serial studies suggest that the combination of cfDNA
with protein C and MODS scores may yield even stron-
ger predictive power.
• We are currently validating our findings prospec-
tively with consecutive enrollment in a large, multicen-
ter, observational study (ClinicalTrials.gov Identifier:
NCT01355042).
• The cfDNA from sepsis patients appears to be host
derived.
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